

Praluent[®] (alirocumab) – Expanded indication

- On March 11, 2024, <u>Regeneron announced</u> the <u>FDA approval</u> of <u>Praluent (alirocumab)</u>, as an adjunct to diet and other low density lipoprotein cholesterol (LDL-C)-lowering therapies in pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.
- Praluent is also approved:
 - To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease
 - As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemia, including HeFH, to reduce LDL-C
 - As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.
- The approval of Praluent for the expanded indication was based on a randomized, placebo controlled, double blind study in 153 pediatric patients aged 8 to 17 years with HeFH. Patients were randomized to receive Praluent or placebo.
 - At week 24 in the group receiving treatment every 4 weeks, the treatment difference between the Praluent and placebo groups in least squares (LS) mean LDL-C percent change from baseline was -31.4% (97.5% CI: -45.0, -17.9; p < 0.0001).
- The recommended dose of Praluent for the treatment of pediatric patients with HeFH and with a body weight less than 50 kg is 150 mg once every 4 weeks administered subcutaneously (SC). If the LDL-C lowering response is inadequate, the dosage may be adjusted to 75 mg SC once every 2 weeks.
- The recommended dose of Praluent for the treatment of pediatric patients with HeFH and with a body weight of 50 kg or more is 300 mg once every 4 weeks administered SC. If the LDL-C lowering response is inadequate, the dosage may be adjusted to 150 mg SC once every 2 weeks.
- Refer to the Praluent drug label for dosing for its adult indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.